Related Experiment Videos

Dislodgment and accelerated degradation of Ras

R Haklai1, M G Weisz, G Elad

  • 1Department of Neurobiochemistry, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel.

Biochemistry
|March 7, 1998
PubMed

Insights

S-trans,trans-farnesylthiosalicylic acid (FTS) dislodges oncogenic Ras proteins from cell membranes, leading to their degradation and reduced cellular levels. This specific action inhibits cancer cell growth, offering a targeted therapeutic approach.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Ras oncoproteins are crucial for cancer cell transformation.
  • Membrane anchorage of Ras is essential for its activity.
  • Farnesylcysteine is a key component for Ras membrane binding.

Purpose of the Study:

  • To investigate the mechanism of S-trans,trans-farnesylthiosalicylic acid (FTS) in inhibiting Ras-transformed cells.
  • To determine if FTS specifically interferes with Ras functions.
  • To elucidate FTS's effect on Ras membrane localization and degradation.

Main Methods:

  • Treatment of H-Ras-transformed (EJ) cells and Rat-1 cells with FTS.
  • Analysis of Ras protein levels and membrane localization.
  • Measurement of Ras protein half-life.
  • Dose-response studies of FTS effects.

Main Results:

  • FTS dislodges Ras from cell membranes, facilitating its degradation and reducing total cellular Ras.
  • Ras degradation was rapid, with a half-life of 10 hours in FTS-treated cells versus 27 hours in controls.
  • FTS demonstrated dose-dependent effects and selectivity towards oncogenic Ras.
  • FTS did not affect normal Ras isoforms or other membrane proteins.

Conclusions:

  • FTS specifically targets Ras membrane docking, leading to enhanced protein degradation.
  • This mechanism underlies FTS's ability to inhibit the growth of Ras-transformed cancer cells.
  • FTS represents a potential therapeutic agent for cancers driven by oncogenic Ras.

Related Concept Videos